Lipocine Inc. (LPCN): Nasdaq/NYSE listing notice — Lipocine gets 180-day Nasdaq extension to June 5, 2023 for $1 bid compliance

Lipocine Inc.

Received Nasdaq notice granting additional 180 days, until June 5, 2023, to meet $1 minimum bid requirement.
Failed to regain compliance during initial 180-day period that ended December 5, 2022.
Eligible for extension because it meets other listing standards and has indicated intent to cure via reverse stock split.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Lipocine Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

December 6, 2022, the Company received notification from Nasdaq indicating that the Company will have an additional 180-day grace period, until June 5, 2023, to regain compliance with the Nasdaq Marketplace Rule’s $1.00 minimum bid requirement. The notification indicated that the Company did not regain compliance during the initial 180-day grace period provided under the rule. In accordance with Nasdaq Marketplace Rule 5810(c)(3)(A), the Company is eligible for the additional grace period because it meets the continued listing requirement for market value of publicly held shares and all other

View on SEC.gov

Browse all listing & compliance notices →

Lipocine Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-034767

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.